Imaging Study of a TROP2 Binder in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

ConditionsMetastatic Urothelial Carcinoma Breast Cancer TNBC - Triple-Negative Breast Cancer Hormone Receptor Positive HER-2 Negative Breast Cancer NSCLC

Trial statusNot yet recruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorRayzeBio, Inc.

About this trial

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of a TROP2 binder in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.

Eligibility criteria

Qualifiers

Are at least 18 years old at the time of signing the informed consent form (ICF)

Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC

Disqualifiers

TROP2-targeting antibody-drug conjugates (ADCs) such as sacituzumab govitecan or datopotamab deruxtecan, should be discontinued at least 90 days prior to administration of RYZ211 and RYZ212

For Women of Childbearing Potential: Are pregnant or breastfeeding

Trial design

Treatments tested in this trial

RYZ211/212

Treatment groups

40 Participants

are divided into 1 treatment group

Locations

Research Facility Christchurch New Zealand

Sponsors and collaborators

RayzeBio, Inc.

Lead sponsor

Source ClinicalTrials.gov